Attachment of rhodosaminylanthracyclinone-type anthracyclines to the hinge-region of monoclonal antibodies

• Published in: Bioconjugate chemistry Vol. 1; no. 2; pp. 100 - 107
• Main Authors: Hermentin, P, Doenges, R, Gronski, P, Bosslet, K, Kraemer, H. P, Hoffmann, D, Zilg, H, Steinstraesser, A, Schwarz, A
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 01.03.1990
• Subjects: Anthracyclines; Antibiotics, Antineoplastic - chemical synthesis; Antibiotics, Antineoplastic - chemistry; Antibodies, Monoclonal; Antigen-Antibody Complex - analysis; Antigens, Neoplasm - analysis; Antigens, Neoplasm - immunology; Binding Sites; Drug Stability; Hexosamines - chemical synthesis; Hexosamines - chemistry; Humans; Indicators and Reagents; Kinetics; Magnetic Resonance Spectroscopy; Molecular Structure; Protein Binding; Structure-Activity Relationship
• ISSN: 1043-1802; 1520-4812
• DOI: 10.1021/bc00002a003

We have found that a maleimidobenzoyl spacer attached to OH-4' of the rhodosamine moiety of rhodosaminylanthracyclinone-type anthracyclines is most suitable for the attachment of these drugs to carriers, providing important advantages: The spacer is selectively and most readily introduced into the rhodosamine moiety of the drugs, is stable enough for proper handling of the derivatives, and can easily be attached to thiol groups of carrier systems such as reduced monoclonal antibodies. The anthracyclines can be liberated from the conjugates by mere hydrolysis, requiring neither hydrolytic enzymes nor acidic pH. Liberation of the drugs can, moreover, be affected by the presence of the appropriate substituents Z on the phenylene ring of the spacer, thus allowing slowed or enhanced liberation of the cytostatically active drug. The corresponding p-maleimidobenzoyl derivatives of beta-rhodomycin I, N,N-dimethyldaunorubicin, and rodorubicin have been attached to thiol groups of the hinge region of reduced monoclonal antibody BW 494/32, directed against a pancreatic cancer associated glycoprotein antigen, resulting in MoAb BW 494/32 conjugates, carrying 4.8-6.8 mol of cytotoxic residues/mol of MoAb. Rodorubicin was similarly attached to MoAb BW 575/931/2, directed against a small cell lung cancer associated antigen and to MoAb BW 431/26, recognizing an epitope detectable on carcinoembryonic antigen. The results provide evidence that the newly developed method of coupling of anthracyclines to the hinge region of monoclonal antibodies may be of broader use.